Streetbeat News

Stock Prices

BRK

JNJ

Hedge fund billionaires, including Warren Buffett and Ray Dalio, have been selling shares of Johnson & Johnson (JNJ) in the third quarter, as revealed by recent 13F filings. JNJ, a dividend king and Fortune’s World's Most Admired Company in 2023, has seen a decrease in hedge fund holdings. Buffett's Berkshire Hathaway (BRK) fully exited its position, while Dalio's Bridgewater Associates and other firms like Lazard Asset Management and Alliancebernstein reduced their stakes. Challenges such as upcoming patent expiration and litigation issues may be influencing these decisions.

Portfolio Pulse from Surbhi Jain

November 17, 2023 | 12:58 pm

PALI

Maxim Group analyst Naz Rahman has upgraded Palisade Bio (NASDAQ:PALI) from Hold to Buy and set a price target of $1.5 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:58 pm

Masanori Mochida, President of Goldman Sachs Japan, is stepping down after 38 years. His departure is part of a move for fresh leadership as the firm faces increased competition in Japan. Mochida was instrumental in establishing Goldman's presence in Japan, competing with domestic banks. His retirement aligns with a growing interest in Japanese investments due to corporate governance reforms and shareholder activism. Mochida's post-retirement plans may involve rugby, reflecting his past interest in the sport.

Portfolio Pulse from Anusuya Lahiri

November 17, 2023 | 12:52 pm

AZN

DSKNY

GILD

The FDA has approved AstraZeneca's Truqap in combination with Faslodex for treating HR-positive, HER2-negative advanced or metastatic breast cancer with specific biomarker alterations. This approval positions AstraZeneca to compete with Gilead Sciences' Trodelvy in the breast cancer treatment market. The approval is based on Phase 3 trial results showing a significant reduction in disease progression or death. AstraZeneca is also set to receive a milestone payment from Astex Therapeutics upon the first U.S. sale and future royalties.

Portfolio Pulse from Vandana Singh

November 17, 2023 | 12:46 pm

YTRA

Yatra Online (NASDAQ:YTRA) reported Q2 earnings with an EPS of $-0.03, which was in line with estimates. However, revenue decreased by $7.22 million compared to the same period last year. The company's past earnings performance shows variability in EPS and revenue, with a notable drop in share price following the last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:40 pm

TWST

Twist Bioscience anticipates Q1 FY24 revenue to be between $67M-$68M, surpassing the consensus estimate of $62.98M. The company also projects a gross margin of approximately 38%-39% for the same period.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:38 pm

TWST

Twist Bioscience (NASDAQ:TWST) reported Q4 earnings with an EPS of $-0.81, beating estimates by 11.96% against an expected $-0.92. Revenue increased by $9.64 million compared to the same period last year. The company had previously beaten EPS estimates last quarter, which resulted in an 11.18% share price increase the following day.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:35 pm

ADI

CMAX

CYBN

EXPE

GLOB

GPS

HUBB

NSSC

WSM

Several top Wall Street analysts have updated their price targets and ratings for various companies. Telsey Advisory Group raised Williams-Sonoma's target and maintained an Outperform rating. Piper Sandler increased Globant's target and kept an Overweight rating. Morgan Stanley upgraded Analog Devices and raised its target. UBS downgraded Agilent Technologies and CareMax, cutting their targets. Telsey Advisory Group lifted The Gap's target and maintained a Market Perform rating. JP Morgan upgraded Hubbell and increased its target. HC Wainwright & Co. lowered Cybin's target but maintained a Buy rating. Needham raised Napco Security Technologies' target and maintained a Buy rating. Evercore ISI Group upgraded Expedia Group and boosted its target.

Portfolio Pulse from Lisa Levin

November 17, 2023 | 12:34 pm

YTRA

Yatra Online (NASDAQ: YTRA) reported a significant decrease in sales for Q2, with $11.40 million in sales compared to $18.63 million in the same quarter last year, marking a 38.78% decline.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:32 pm

HUBB

JP Morgan analyst Stephen Tusa upgraded Hubbell (NYSE:HUBB) from Neutral to Overweight and increased the price target from $333 to $335.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:31 pm